ESMO 2021 | Neo-PATH: TAHP for patients with HER2-positive breast cancer
Yeon Hee Park, MD, PhD, Samsung Medical Center, Seoul, Korea, discusses findings from the Phase Ib/II Neo-PATH clinical trial (NCT03991878) investigating the efficacy and toxicity of neoadjuvant chemotherapy with docetaxel plus atezolizumab plus herceptin SC and pertuzumab (TAHP) in patients with HER2-positive stage II/III breast cancer. Prof. Park explains that patients treated with TAHP showed a pathologic complete response (pCR) rate of 62%, comparable to standard of care therapy with TCHP (docetaxel + carboplatin + trastuzumab + pertuzumab), but with a considerably improved toxicity profile. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Prof. Park reports consultancy/advisory role for AstraZeneca, Pfizer, Eisai, Roche, Daiichi-Sankyo, Eli Lilly, and Novartis Pharmaceuticals.
Prof. Park reports patents and royalties from Hanmi.
Prof. Park reports honoraria from AstraZeneca, Pfizer, Eisai, Roche, Daiichi-Sankyo, and Novartis.
Prof. Park reports grant/research funding from AstraZeneca, Merck, Pfizer, Novartis, Alteogen, and Roche.
